Sugi Predict

Sugi Predict / Compounds / Biotin

Biotin

Biotin

SCHEMBL3425472

NCCCCCCCCCCCC(=O)O.O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.85

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 6/20 0.85
▸ MEN1 O00255 1/20 0.85
▸ ABL1 P00519 1/20 0.85
▸ LMNA P02545 1/20 0.85
▸ PKM P14618 1/20 0.85
▸ IDE P14735 1/20 0.85
▸ MAPK1 P28482 1/20 0.85
▸ KMT2A Q03164 1/20 0.85
▸ RIN1 Q13671 1/20 0.85
▸ L3MBTL1 Q9Y468 1/20 0.85
▸ HLCS P50747 6/20 0.64
▸ CA12 O43570 7/20 0.53
▸ CA1 P00915 7/20 0.53
▸ CA2 P00918 7/20 0.53
▸ CA9 Q16790 7/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biotin SCHEMBL770770 1.00 TDP1 (0.85) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL739967 1.00 TDP1 (0.85) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL16653090 0.99 TDP1 (0.83) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL6865574 0.96 TDP1 (0.87) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL27481189 0.95 TDP1 (0.81) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL453833 0.95 TDP1 (0.90) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL8672971 0.94 TDP1 (0.76) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL8432238 0.94 TDP1 (0.76) TDP1MEN1ABL1LMNAPKM
Biotin SCHEMBL2057282 0.94 TDP1 (0.87) TDP1MEN1ABL1LMNAPKM
SCHEMBL16141190 0.94 TDP1 (0.97) TDP1MEN1ABL1LMNAPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111712236-A Compositions comprising lipid-based nanoparticles for the treatment of diabetes SDG公司 2020-09-25 — — CN claimed
CN-110612114-A Lipid-based nanoparticles with enhanced stability SDG公司 2019-12-24 — — CN claimed
CN-101917971-A Orally bioavailable lipid-based structures SDG INC AN OHIO CORP 2010-12-15 — — CN claimed
US-20220403377-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. 2022-12-22 — — US disclosed
US-11312957-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2022-04-26 — — US disclosed
CN-111712236-A Compositions comprising lipid-based nanoparticles for the treatment of diabetes SDG公司 2020-09-25 — — CN disclosed
US-10676740-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2020-06-09 — — US disclosed
CN-110612114-A Lipid-based nanoparticles with enhanced stability SDG公司 2019-12-24 — — CN disclosed
US-20190345498-A1 MODIFIED iRNA AGENTS BANK OF AMERICA, N.A. 2019-11-14 — — US disclosed
US-20180258427-A1 MODIFIED iRNA AGENTS BANK OF AMERICA, N.A. 2018-09-13 — — US disclosed
US-20160264968-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. 2016-09-15 — — US disclosed
US-9394540-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2016-07-19 — — US disclosed
US-20140316124-A1 MODIDIFED iRNA AGENTS BANK OF AMERICA, N.A. 2014-10-23 — — US disclosed
US-8796436-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2014-08-05 — — US disclosed
US-20130211063-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-15 — — US disclosed
US-8507661-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2013-08-13 — — US disclosed
CN-101917971-A Orally bioavailable lipid-based structures SDG INC AN OHIO CORP 2010-12-15 — — CN disclosed
US-20100292455-A1 MODIFIED iRNA AGENTS ALNYLAM PHARMACEUTICALS (US) 2010-11-18 — — US disclosed
US-7745608-B2 Modified iRNA agents ALNYLAM PHARMACEUTICALS, INC. (US) 2010-06-29 — — US disclosed
US-20050107325-A1 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs ALNYLAM PHARMACEUTICALS, INC. 2005-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220403377-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 TDP1 174/4885MEN1 630/4885ABL1 4449/4885
US-20190345498-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 TDP1 174/4885MEN1 630/4885ABL1 4449/4885
US-20100292455-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 TDP1 174/4885MEN1 630/4885ABL1 4449/4885
US-20180258427-A1 MODIFIED iRNA AGENTS NCL, HNRNPA0, HNRNPA1 TDP1 174/4885MEN1 630/4885ABL1 4449/4885
US-10676740-B2 Modified iRNA agents NCL, HNRNPA0, HNRNPA1 TDP1 174/4885MEN1 630/4885ABL1 4449/4885
US-20050107325-A1 Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs LDLR, SLC29A1, SLC29A2 TDP1 949/4885MEN1 1466/4885ABL1 4844/4885
US-11312957-B2 Modified iRNA agents NCL, HNRNPA0, HNRNPA1 TDP1 174/4885MEN1 630/4885ABL1 4449/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.